Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications

Oisin F. McElvaney, Takahiro Asakura, Suzanne L. Meinig, Jose L. Torres-Castillo, Robert S. Hagan, Claudie Gabillard, Mark P. Murphy, Leigh B. Thorne, Alain Borczuk, Emer P. Reeves, Ross E. Zumwalt, Yu Mikami, Tomas P. Carroll, Kenichi Okuda, Grace Hogan, Oliver J. McElvaney, Jennifer Clarke, Natalie L. McEvoy, Patrick W. Mallon, Cormac McCarthy, Ger Curley, Matthew C. Wolfgang, Richard C. Boucher, and Noel G. McElvaney

aIrish Centre for Genetic Lung Disease, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Dublin, Ireland
bMarsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
cDepartment of Anaesthesia and Critical Care, Beaumont Hospital, Dublin, Ireland
dRoyal College of Surgeons in Ireland, Dublin, Ireland
eAlpha-1 Foundation, Ireland
fDivision of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
gDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
hDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
iDepartment of Pathology, University of New Mexico School of Medicine, Albuquerque, NM, USA
jDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
kDepartment of Infectious Diseases, St Vincent’s University Hospital, Dublin, Ireland
lCentre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland
mDepartment of Respiratory Medicine, St Vincent’s University Hospital, Dublin, Ireland
nSchool of Medicine, University College Dublin, Dublin, Ireland

Summary

Background Interleukin-6 (IL-6) is elevated in SARS-CoV-2 infection. IL-6 regulates acute-phase proteins, such as alpha-1 antitrypsin (AAT), a key lung anti-protease. We investigated the protease-anti-protease balance in the circulation and pulmonary compartments in SARS-CoV-2 acute respiratory distress syndrome (ARDS) compared to non-SARS-CoV-2 ARDS (nsARDS) and the effects of tocilizumab (IL-6 receptor antagonist) on anti-protease defence in SARS-CoV-2 infection.

Methods Levels and activity of AAT and neutrophil elastase (NE) were measured in plasma, airway tissue and tracheal secretions (TA) of people with SARS-CoV-2 ARDS or nsARDS. AAT and IL-6 levels were evaluated in people with moderate SARS-CoV-2 infection who received standard of care +/- tocilizumab.

Findings AAT plasma levels doubled in SARS-CoV-2 ARDS. In lung parenchyma AAT levels were increased, as was the percentage of neutrophils involved in NET formation. A protease-anti-protease imbalance was detected in TA with active NE and no active AAT. The airway anti-protease, secretory leukoprotease inhibitor was decreased in SARS-CoV-2-infected lungs and cleaved in TA. In nsARDS, plasma AAT levels were elevated but TA samples had less AAT cleavage, with no detectable active NE in most samples.

Induction of AAT in ARDS occurred mainly through IL-6. Tocilizumab down-regulated AAT during SARS-CoV-2 infection.

Interpretation There is a protease-anti-protease imbalance in the airways of SARS-CoV-2-ARDS patients. This imbalance is a target for anti-protease therapy.

Keywords: Alpha-1 antitrypsin; SARS-CoV-2 infection; Neutrophil elastase; Interleukin-6

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a major global health risk with few therapies available to modify its clinical impacts.
ARDS. IL-6 is a major inducer of AAT production by morbidity and mortality of SARS-CoV-2-induced SARS-CoV-2 pathogenesis and is associated with the leukin-6 (IL-6) has been identified as a pivotal cytokine of TMPRSS-2, the serine protease that cleaves theulate the severity of SARS-CoV-2 infection via inhibition SARS-CoV-2 infection. Early in disease, AAT may mod- in inflammatory protein, may influence the trajectory of course. As of September 2021, more than 228 million laboratory-confirmed cases have been documented globally, with over 4.5 million deaths. Alpha-1 antitrypsin (AAT), a major serine protease inhibitor and anti-inflammatory cytokine but as an anti-inflammatory regulator.

Added value of this study
This study shows that the AAT response to SARS-CoV-2 infection is compartmentalized with an appropriate increase in plasma and alveoli but an inadequate response in airways. This underlines a significant, but potentially treatable, protease-antiprotease imbalance in SARS-CoV-2 ARDS as well as highlighting IL-6’s impor- tance in SARS-CoV-2 pathology not only as a pro-inflam-matory cytokine but as an anti-inflammatory regulator.

Implications of all the available evidence
There is unopposed NE activity in the airways of people with SARS-CoV-2 ARDS, which could be amenable to AAT therapy. Our data suggest caution in the use of IL-6 blocking therapies in SARS-CoV-2-infected individuals.

Methodology

Ethics
Ethical approval for patient sampling was in accordance with the Declaration of Helsinki, Good Clinical Practices. Ethical approval for SARS-CoV-2 and nsARDS ICU patient sampling was received from the Beaumont Hospital Ethics Committee (REC #18/52, #17/06 (amended specifically for SARS-CoV-2 ICU subjects)). Further nsARDS patient samples were sourced from the placebo arm of the KARE trial.

Ethical approval for ward level patients treated with tocilizumab was approved by the St. Vincents Healthcare Group Research Ethics Committee.

TA samples from SARS-CoV-2 patients were obtained with informed consent and approval by the University of North Carolina Office of Human Research Ethics, IRB 20-o822).

Patient selection and sampling
Patients from Beaumont hospital, with a laboratory con-firmed SARS-CoV-2 diagnosis (via reverse transcriptase–polymerase chain reaction (RT-PCR) assay of nasopharyngeal swab specimens) requiring ICU admission for intubation and mechanical ventilation for hypoxemic respiratory failure were studied (SARS-CoV-2 ICU, n = 20) (Table 1a,b). Sample size was based on standard cut-offs of 0.05 for type I error and 0.2 for type II error, following observational studies of patients with non-SARS-CoV-2 ARDS. However, unfamiliarity with
the potential breadth of presentations and outcomes in SARS-CoV-2 infection led to our decision to exceed requirements and recruit 20 patients.

Blood samples from the ICU cohort were collected by venipuncture into lithium heparin tubes on admission to ICU and every 2nd day following admission. Plasma was isolated from blood by centrifugation at 350 xg for 10 min. nsARDS patients selected for TA samples (n = 6, Table 2b) were chosen on the basis of a negative RT-PCR of a nasopharangeal swab and moderate to severe ARDS as per BERLIN criteria, TA samples were collected aseptically, by opening the closed suction device, inserting sterile suction tubing and pulling back by no more than 37 cm to obtain an adequate sample. 8 plasma samples were collected from patients enrolled on the placebo arm of the KARE trial. In ward patients with mild SARS-CoV-2 (n = 24, plasma samples were taken pre- and 28 days post tocilizumab infusion. TA samples from SARS-CoV-2 ARDS patients were obtained 1 day post intubation (n = 15), 10 from UNC, 5 from Beaumont hospital. All of the TA control group samples from nsARDS patients were also obtained 1 day post intubation (n = 6). Plasma was also collected from healthy donors (n = 11). All sampled patients were selected at random from a list of medical record numbers, a computer-generated series of random numbers, corresponding to patients with a confirmed infected status. Patients were excluded if they were immunosuppressed, on long-term oral corticosteroids, anti-IL-1, anti-IL-6, or anti-TNF therapy, were pregnant, had active neoplasia, or a history of vasculitis or connective tissue disease. Experiments performed on the samples were undertaken by a blinded investigator who were excluded from the collection of samples and the patients’ clinical care. All experiments involving patient samples were replicated a minimum of 3 times however the total number of samples taken varied depending on potential discharge or death of a patient

**Demographics of patient cohort (n = 20)**

| Age in years | 51.1 +/-13.4 |
| Male/female | 17/3 |
| Days since onset of symptoms | 8.7 +/- 3.9 |
| Symptoms at admission (%) | |
| Fever | 11 (55) |
| Dyspnea | 13 (65) |
| Cough | 13 (65) |
| Sputum production | 2 (10) |
| Myalgia | 3 (15) |
| Fatigue | 2 (10) |
| Anorexia | 2 (10) |
| Nausea | 3 (15) |
| Vomiting | 1 (5) |
| Diarrhea | 2 (10) |
| Chest pain | 1 (5) |
| Circumstances surrounding infection | |
| Close contact with infected person | 3 (15) |
| Community-acquired | 17 (85) |
| Comorbidities | |
| Hypertension | 11 (55) |
| Coronary artery disease | 1 (5) |
| Diabetes mellitus | 2 (10) |
| Obesity | 11 (55) |
| Smoking history | |
| Current | 2 (10) |
| Former | 1 (5) |
| Never | 14 (70) |

**Clinical features of patient cohort at time of ICU admission (n = 20)**

| Temperature > 38 °C | 9 (45) |
| Heart rate > 100 beats per minute | 12 (60) |
| Respiratory rate > 20 breaths per minute | 10 (50) |
| SaO2 < 80% or requiring FiO2 ≥ 60% | 16 (80) |
| Acute confusion | 1 (5) |
| PaO2 | 9.5 +/- 1.6 |
| Mean arterial pressure | 91.6 +/- 16.1 |
| SOFA score | 8.05 +/- 2.3 |
| PaO2/FiO2 on arrival to ICU | 160.5 +/- 60.8 |

**Table 1a: SARS-CoV-2 ARDS patient demographics for plasma studies.**

**Table 1b: SARS-CoV-2 ARDS patient clinical status.**

Measurements in plasma

AAT levels in plasma were measured by immunoturbidimetric assay. Plasma IL-6 was measured by Human IL-6 Quantikine ELISA Kit (R&D). Plasma IL-8 was measured by IL-8/CXCL8 DuoSet ELISA Kit (R&D).

**Antibody and reagent validation**

All antibodies, reagents and cell lines have been obtained from commercial vendors. Antibodies were used in accordance with the protocols outlined on their corresponding datasheets. Performance for western blotting was validated by inclusion of purified standards of target proteins. Amplicon specificity was verified by amplicon visualisation using agarose gel electrophoresis.

**Western blot analysis of plasma and airway samples**

Western blot analysis was performed on patient samples (plasma and TAs) for AAT and SLPI and NE from SARS-CoV-2 ARDS patients (plasma samples n = 20, TA samples n = 15) along with a control group samples from nsARDS patients (plasma samples n = 8, TA samples n = 6). Total protein quantities were measured with
a BCA Protein Assay Kit (Pierce®). HRP-coupled primary antibodies for AAT (1:2000, GR286990-3, Abcam), NE (1:1000, clone # 950317, MAB91671, R&D systems) and SLPI (1:2000, AF1274, R&D systems, RRID: AB_2302508), were incubated overnight at 4 °C with the target protein, then probed with a secondary HRP-linked antibody (1:1000, 7076S, Cell signalling technology, RRID: AB_631728, respectively). Proteins were detected with Immobilon ECL Ultra Western HRP Substrate (Merck Millipore) using a ChemiDoc™ Imaging System (Bio-Rad). Semi-quantification by densitometry was performed with ImageJ software (NIH).

**Co-immunoprecipitation of alpha-1 antitrypsin and IL-8**

Binding capacity of IL-8 by AAT was determined by immunoprecipitation of AAT from plasma of healthy donors, or people with SARS-CoV-2 infection prior to and post treatment with tocilizumab, using an anti-AAT antibody (clone 202808, R&D Systems, RRID: AB_2301508) immobilised on amine-reactive beads according to manufacturers’ instructions (Pierce co-immunoprecipitation kit, Thermo). Plasma (20 µl) was diluted 1:5 in Dulbeccos PBS and pre-cleared of non-specifically binding proteins. AAT was then captured overnight at 4 °C with 5 µg antibody per reaction. Bound protein was eluted using 60 µl of elution buffer and assayed by ELISA for AAT or IL-8 at a 1:20 dilution together with flow through fraction and control eluate from beads that lacked antibody.

**AAT and NE activity analysis**

AAT-mediated NE inhibition by SARS-CoV-2 plasma (n = 20) and NE activity and AAT-mediated NE inhibition in SARS-CoV-2 TAs (n = 5) was assessed by fluorescence resonance energy transfer (FRET) analysis as described previously.12 AAT was incubated at various concentrations with NE for 20 min at 37 °C and added to a 96 well plate. A working solution of 20 µM of FRET substrate Abz-Ala-Pro-Glu-Glu-Ile-Met-Arg-Arg-Gln-EDDnp was added (3230-v, Peptanova GmbH). Upon addition, the kinetic reaction was immediately measured at 37 °C, over 20 min with readings occurring every 20 s using a Spectra Max M3 microplate reader.

**Control and SARS-CoV-2 autopsy lungs**

Non-disease control human lungs from individuals without a history of pulmonary disease and size mismatch unsuitable for transplantation were provided by the University of North Carolina (UNC) Tissue Procurement and Cell Culture Core (protocol #03-1396) (n = 4). SARS-CoV2 infected autopsy lungs (no hospital admission, no intubation) were provided by Drs. Ross E. Zumwalt (University of New Mexico, Albuquerque, NM), Dr. Alain Borczuk (Weill Cornell Medicine, New York, NY) and Dr. Leigh B. Thorne (University of North Carolina at Chapel Hill, Chapel Hill, NC) (n = 8) . Immunohistochemistry was performed according to protocols as previously described.13 To probe for specific proteins, primary antibodies for SLPI (1:4000, ab175175, Abcam, RRID:AB_443693), AAT (1:800, A0012, Dako, RRID: AB_2335672), NE (1:100, MAB91671, R&D systems) and citrullinated histone H3 (1:2000, ab5103, abcam, RRID:AB_304752) were used in 4% normal donkey serum in PBST (phosphate-buffered saline containing 0.1% Triton X-100). Secondary antibodies included biotinylated donkey anti-mouse anti-mouse IgG (1:200); Alexa Fluor 488 donkey anti-rabbit IgG (1:1000, Thermo, RRID: AB_2536180) and Alexa Fluor 647 donkey anti-mouse/IgG (1:1000, Thermo, RRID: AB_2556546) Alexa Fluor 555 donkey anti-mouse IgM (1:1000, Thermo, RRID: AB_2335672) and Alexa Fluor 647 donkey anti-mouse/rabbit IgG (1:1000). For the immunofluorescence study, the Vector® TrueVIEW Autofluorescence Quenching Kit (Vector laboratories) was used to reduce background staining. Coverslipped slides were scanned using the following settings: Olympus VS200 whole slide scanner microscope with a 60X, 1.4 NA objective, an Olympus confocal microscope with a 20X, 0.75 NA / 60X, 1.4 NA objective, or a Leica Stellaris confocal microscope with a 20X, 0.75 NA / 63X, 1.4 NA objective.

**AAT and ST6GAL1 mRNA expression**

Hep-G2 cells (HB-8085, ATCC, RRID: CVCL_0027) were cultured in Eagles Modified Essential Medium (EMEM, Sigma-Aldrich), supplemented with 10% (w/v) Fetal Calf Serum (FCS, Sigma-Aldrich) and 0-2% (v/v) Primocin (InVivoGen). Hep-G2 cells were stimulated with IL-6 (180 pg/ml) (Abcam) for 6 to 36 h to induce AAT expression. A 12 well plate, containing 2 x 10³ cells/well in 1 ml EMEM, was incubated overnight at 37 °C, following which fresh media supplemented with IL-6 (180 pg/ml) +/- tocilizumab (50 µg/ml, Roche) was added. Plasma sourced from patients with SARS-CoV2 on the first day of their ICU admission was used for stimulation of AAT production in Hep-G2 cells. A 24 well plate format was used, incubating 8 x 10⁴ cells per well in 500 µl of EMEM per well (overnight at 37 °C), following which media was removed and replaced with 250 µl of plasma from six SARS-CoV-2 ICU patients +/- tocilizumab (50 µg/ml) or six nSARDS patients +/- tocilizumab.
After stimulation with either IL-6 or plasma from ICU based SARS-CoV-2 patients/nsARDS patients, Hep-G2 cells were lysed with radioimmunoprecipitation assay buffer (RIPA) (Thermo) containing 1% Triton X-100 and a protease inhibitor cocktail (Sigma-Aldrich) for 2 h at 4 °C, mRNA extracted using the PureLink RNA Mini Kit (Ambion), reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen). cDNA was subjected to 45 cycles of amplification for quantitative real-time polymerase chain reaction (qPCR) using the Master I LightCycler® 480 Kit (Roche) and specific primers targeting AAT (forward primer: 5’-ATGCTGCCACAGACAGATA-3’, reverse primer: 5’-CTGAAGGCAACTCAGCCA-3’) and ST6GAL1 Forward: 5’-AGG TGT GCT GTT GTG TCG-3’ Reverse: 5’-TGT TGG AAG TTG GCT GTG G-3’). Analyses were performed on a LightCycler 480® instrument (Roche) and gene expression calculated with the 2-ΔΔCt method using GAPDH as the reference gene (Forward: 5’- CAT GAG AAG TAT GAC AAC AGC CT -3’, Reverse: 5’-AGT CCT TCC ACG ATA CCA AAG T -3’).

Isoelectric focusing and immunoblotting
Immunofixation of plasma AAT glycoforms was performed via isoelectric focusing gel electrophoresis (Sebia HYDRASYS) as previously described. This method was used not only for the verification of AAT phenotypes in SARS-CoV-2 but also to assess glycosylation patterns of AAT in ICU patients and in ward patients receiving standard of care (SOC) +/- tocilizumab matched for similar starting AAT levels and inflammatory profiles. Isoelectric focusing and immunoblotting was also used to determine the difference in AAT glycosylation between the plasma and tracheal aspirates in SARS-CoV-2 ARDS, nsARDS and an anonymised cystic fibrosis patient with known NE in their TA as an inflammatory control.

AAT sialylation
To analyse AAT sialylation in SARS-CoV-2 subject plasma, AAT was isolated from plasma samples by an Alpha-1 Antitrypsin Select Resin/Tricorn column as previously described. Isolated samples were chromatographed by fast protein liquid chromatography (AKTA instrument equipped with UV detector and an automatic fraction collector). Samples were denatured by incubation at 100 °C with 1% (w/v) SDS and 1% (w/v) DTT and incubated subsequently overnight with PNGase F [LZ-rPNGaseF-kit] in NP-40 buffered solutions to release N-glycans. The released glycans were labelled with procainamide, labelled samples analysed by hydrophilic interaction ultra-performance liquid HILIC-UPLC (ACQUITY UPLC) controlled by Empower software version 3, build 3471), and SARS-CoV-2 sialylation profiles compared to healthy controls (Ludger Ltd. Culham science centre, Oxfordshire, UK).

Statistical analysis
Statistical analysis was performed in Prism (v9.2, Graphpad). Results were presented as absolute numbers, means ± standard deviation or as percentages as appropriate. Comparisons between two groups with normally distributed data utilized paired t tests. For comparisons of three or more groups, ANOVA was used. Multiple comparisons across multiple groups were by 2-way ANOVA, with P values derived by Tukeys’ post-hoc multiple comparison test. A value of P < 0.05 was considered statistically significant. Normality of data was tested using both the D’Agostino & Pearson test (sample size allowing) and Shapiro-Wilk test and was confirmed for each group. Multinomial logistic regression (R version 4.1.2) was used to assess the association of the potential disease modifying or confounding factors, age, sex and AAT level at recruitment, with patient cohort and likelihood ratio testing was used to determine interaction between factors.

Role of funders
Funders had no role in study design, data collection, data analyses, interpretation, or writing of this manuscript.

Results
Patient population characteristics
The demographics of the patient populations are shown in Tables 1a–1c, 2a, 2b; control population in supplemental Table 1. Healthy controls were similar in age to patients admitted to ICU with SARS-CoV-2, (49 ± 16 vs 51 ± 13 years) and, though the other cohorts studied were older on average, age was not seen to associate significantly with one cohort over controls (61.3 ± 8 years, P = 0.457, and 60.8 years, P = 0.285, for nsARDS and SARS-CoV-2 infection requiring non-ICU hospitalisation, respectively). Sex of the patients was not significantly associated with any of the studied conditions.

By comparison with other cohorts of patients with severe SARS-CoV-2 infection requiring intensive care recruited before vaccination availability, our population was of similar age (51 ± 13 vs 58 ± 9 years). Patients

| SARS-CoV-2 patients receiving standard of care (SOC) +/- tocilizumab | SOC | SOC + Tocilizumab |
|---|---|---|
| Number of patients | 6 | 24 |
| M/F | 4/2 | 16/8 |
| Age | 60.8+/- 11.1 | 60.8+/- 13.6 |
| SARS-CoV-2 Pos+ via nasal swab | 6 (100) | 24 (100) |
| Mortality Y/N | 0 (0) | 2 (12) |

Table 1c: Demographics of ward level patients receiving SOC+/- tocilizumab.
Form and activity of AAT, NE and SLPI in SARS-CoV-2 plasma and TAs

Plasma AAT was not complexed or cleaved (Figure 2a) and was fully active against NE (Figure 2b). TA from intubated subjects with SARS-CoV-2 (n = 15) and nsARDS (n = 6) contained cleaved AAT and AAT-NE complexes on Western analysis (Figure 3a (i)). In the SARS-CoV-2 TA, the AAT was cleaved to a greater extent than the nsARDS TA, and significant free NE was detected by Western blot analyses as well as cleaved SLPI in contrast to nsARDS (Figure 3a (ii) and (iii), respectively). Of all 6 nsARDS TAs only 1 had free NE (Supplemental Figure 1a). As 10 of the SARS-CoV-2 TA samples were in 6M urea, NE activity could not be directly measured as 6M urea interferes with NE activity assays. Five of the SARS-CoV-2 TA samples had no 6M urea added and sufficient volume for FRET protease activity assay. This detected active NE in all five which, was fully inhibited by the addition of plasma purified AAT (Figure 2d).

Commensurate with the Western analysis, active NE was only detected in one of the TA from nsARDS patients. The NE burden in SARS-CoV-2 infected airways, compared to nsARDS, was further demonstrated by iso-electric focusing with immunoblotting for AAT in TAs (supplemental Figure 2a). Glycosylated AAT was present and well defined in the tracheal aspirates of individuals with nsARDS who had no active NE but AAT was significantly degraded in SARS-CoV-2-ARDS TA samples where free NE was detectable.

IHC analysis of autopsy SARS-CoV-2 lungs

Immunohistochemistry (IHC) of control lungs identified SLPI in both superficial epithelia and submucosal glands (SMGs) (Figure 4b). In contrast, in SARS-CoV-2 autopsy lungs, SLPI expression was decreased in both superficial epithelia and SMGs (Figure 4b). Based on previous data demonstrating SARS-CoV-2 infection of superficial airway epithelia, these data are consistent with virus-induced suppression of SLPI expression. AAT and NE were localized in lungs from 8 subjects who died from SARS-CoV-2 infection. An increase in immuno-detectable AAT was observed in the SARS-CoV-2 autopsy lungs, mainly as free AAT filling alveolar lumens (Figure 4b). There was no increase in neutrophil numbers in the SARS-CoV-2 lungs compared to controls as quantified by ELANE IHC (Figure 4b). AAT appeared by IHC to be in excess of NE in SARS-CoV-2 lungs as indexed by increased AAT/NE (SERPINA1/ELANE) ratios (Figure 4b (iv)) and the increased number of AAT/NE double-positive cells (neutrophils associated with AAT) (Figure 4b (iv)). Notably, a fraction of neutrophils in SARS-CoV-2 autopsy lungs, particularly in the interstitium, were characterized by NET formation as indicated by positive staining for citrullinated histone H3 (Figure 4c (i) and (iii)).

Plasma AAT levels in SARS-CoV-2 ARDS

Plasma AAT levels in SARS-CoV-2 patients on admission to the ICU (3.29 ± 0.8 g/L) were significantly higher than in healthy controls (Mean: 1.74 ± 0.11 g/L, p < 0.001, Figure 1a) but similar to nsARDS subjects (Mean: 2.9 ± 0.8 g/L, p = 0.5273, Figure 1a). The higher levels of AAT in plasma in both ARDS groups persisted throughout their ICU stay (Figure 1b, c). Elevated AAT was prominently associated with each of the conditions, as expected due to its nature as an acute phase protein (SARS-CoV-2 vs healthy controls: log odds 10-93, SE 4.3, P = 0.011).
Figure 1. AAT levels in plasma of healthy donors and patients in ICU with SARS-CoV-2 or nsARDS.

a. Plasma AAT levels on first day of admission into ICU with SARS-CoV-2 (n = 11, 3.204 g/L +/- 0.768) or nsARDS (2.923 g/L +/- 0.7984) as compared to healthy controls (n = 11) (1.73 g/L +/- 0.104), P < 0.0001, P = 0.0013 respectively with no significant difference between SARS-CoV-2 and nsARDS at day 1. Significance was tested for by one way ANOVA with Tukey multiple comparison test (*p < 0.05). b. Plasma AAT levels in SARS-CoV-2 patients over the first 15 days of ICU admission (Mean: 3.2 g/L +/- 0.7 n = 20). c. Plasma alpha-1antitrypsin (AAT) levels in non-SARS-CoV-2 ARDS patients over the first 15 days of ICU admission (2.87 g/L +/- 0.607) (n = 8).
AAT and ST6GAL1 response to IL-6 and SARS-CoV-2 ARDS and nsARDS plasma

AAT expression in hepatic cells, in response to IL-6 administration, at a dose similar to that seen in SARS-CoV-2 ARDS plasma, is delayed, peaking at 24 h after IL-6 administration (Figure 5a). SARS-CoV-2 plasma and nsARDS control plasma also stimulated AAT mRNA production from hepatic cells in a similar fashion (Figure 5b). These responses were largely blocked by tocilizumab, an antibody against the IL-6 receptor (Figure 5b), intimating that IL-6 is the major component of SARS-CoV-2 plasma contributing to AAT upregulation. IL-6 in SARS-CoV-2 and nsARDS control group plasma also induced ST6GAL1 expression, the enzyme mediating sialylation of AAT (Figure 5c). This was also blocked by tocilizumab, confirming the contribution of IL-6 to sialylation of AAT. The percentage sialylation of AAT in plasma from subjects with severe SARS-CoV-2 infection, collected 8 days into ICU admissions, was increased compared to healthy control plasma $(P = 0.0211)$ (Figure 5d). Concurrent with this, there was also an increased abundance of M0 and M1 bands detected in SARS-CoV-2 patients (Figure 5e), and this increase in AAT sialylation glycoforms persisted throughout the ICU stay.

AAT and IL-6 levels pre-and post-pan-IL-6 receptor antagonist

Given the role of IL-6 signalling in regulating AAT secretion, we next examined the effect of tocilizumab on AAT in vivo, during acute SARS-CoV-2 infection.
Plasma samples were collected from ward level care patients with confirmed SARS-CoV-2 infection pre- and post-tocilizumab infusion. The initial plasma AAT level (2.47 ± 0.2 g/L) was significantly higher than healthy controls (P < 0.0001). Patients were dosed with 8 mg/kg tocilizumab (n = 24, Table 1c). A significant decrease in AAT plasma levels was noted 28 days post-tocilizumab (1.3 g/L ± 0.2, P < 0.0001) (Figure 6a). In contrast, IL-6 levels remained elevated throughout the 28-day course in these patients (Figure 6b, NS, P = 0.0998). These changes were reflected in the increased IL-6/AAT ratio at day 28 post tocilizumab.

Figure 3. Form and function of AAT, NE and SLPI in plasma and tracheal aspirates (TA) of SARS-COV-2 ARDS patients.

(a) Western blot analysis of AAT in SARS-COV-2 TAs from individual SARS-CoV-2 ARDS patients labelled P1,P2,P3,P4 and the control group of nsARDS patients labelled P1,P2,P3 demonstrates cleavage of AAT and AAT-NE complexes with significantly more cleavage of AAT seen in the SARS-Cov-2 TA samples. (ii, iii) Western blot analysis of NE in the TAs of the same individuals patients show free NE and cleaved SLPI in SARS-Cov-2 TAs in contrast to the nsARDS control group. b. FRET analysis reveals active NE in all 5 TAs from SARS-COV-2 patients on their 1st day of ICU admission and inhibition with exogenous AAT. Only 1 of the 5 nsARDS TA samples demonstrated active NE which was inhibited by exogenous AAT. Significance was tested for by paired T test; *p < 0.05.
Figure 4. Protein expression in control and SARS-CoV-2 autopsy lungs by immunohistochemistry.

a. SLPI protein localization in large airways of control (n = 4) (i) and SARS-CoV-2 autopsy lungs (n = 8) (ii). Quantification of SLPI protein-stained area in each submucosal gland and epithelium (iii). b. Fluorescent immunohistochemistry of NE (ELANE) and AAT (SERPINA1) in alveoli of control and SARS-CoV-2 autopsy lungs (i–iii). Quantification of each protein-stained area, AAT/NE ratio, and colocalization between AAT and ELANE (iv). c. Fluorescent immunohistochemistry of NE (ELANE) and citrullinated histone H3 (Cit H3) in alveoli of control and SARS-CoV-2 autopsy lungs (i, ii). Arrows showed colocalization of ELANE and Cit H3 (ii). Quantification of co-localization between ELANE and Cit H3 (iii). Histogram bars and error bars represent mean ± SEM. *P < 0.05, **P < 0.01. Scale bars = 100 μm (a); 20 μm (b); 50 μm (c); 10 μm (Cii). Significance was tested for by Mann-Whitney test (U-test).
Figure 5. Upregulation of AAT and ST6GAL1 mRNA in response to IL-6 and SARS-CoV-2 ARDS and nsARDS plasma.

a. AAT expression in HepG2 cells stimulated with IL-6 over time by RT-qPCR. AAT mRNA production is significantly and consistently raised from 12 h reaching its peak at 24 h. Significance was tested for by two-way ANOVA with Tukey post-hoc test* $p < 0.05$.

b. AAT Fold change in w/o Tocilizumab and with Tocilizumab at 24h.

c. ST6GAL1 Fold change in w/o Tocilizumab and with Tocilizumab at 24h.

d. % Sialylation in HC, D1, and D8.

e. Western blot analysis of MM, MS, ZZ, and SARS-CoV-2 proteins.
zumab treatment (supplemental Figure 4a).

compared to pre-infusion binding (P = 0.0011) and in comparison to healthy controls (P = 0.0002), reflecting the diminished glycosylation of AAT upon tocilizumab treatment (supplemental Figure 4a).

The SOC patients exhibited AAT hyper-glycosylation at the beginning and end of their treatment, denoted by M0 and M1 bands, whereas the tocilizumab treated patients at day 28 showed no Mo or M1 bands despite initially manifesting a hyper-glycosylated AAT profile prior to treatment (Figure 6d). The degree of AAT/IL-8 binding in SARS-CoV-2 samples post tocilizumab infusion was significantly reduced compared to pre-infusion binding (P = 0.0046) (Figure 6c), which suggested that IL-6 was no longer regulating AAT production. In ward level COVID-19 patients who received standard of care treatment (SOC) without tocilizumab (n = 6), AAT levels remained elevated (2.54 g/L ± 0.4 to 2.27 g/L ± 0.4 at day 28, NS, P = 0.1856) (supplemental Figure 3b). Similarly, the IL-6 levels in SOC patients showed no significant decline from their first recorded levels (19.016 pg/ml ± 10.35 pg/ml compared to 15.823 pg/ml ± 13.08; NS, P = 0.885, supplemental Figure 3a).

The SOC patients exhibited AAT hyper-glycosylation at the beginning and end of their treatment, denoted by M0 and M1 bands, whereas the tocilizumab treated patients at day 28 showed no Mo or M1 bands despite initially manifesting a hyper-glycosylated AAT profile prior to treatment (Figure 6d). The degree of AAT/IL-8 binding in SARS-CoV-2 samples post tocilizumab infusion was significantly reduced compared to pre-infusion binding (P = 0.0011) and in comparison to healthy controls (P = 0.0002), reflecting the diminished glycosylation of AAT upon tocilizumab treatment (supplemental Figure 4a).

**Discussion**

SARS-CoV-2-infected subjects exhibited evidence of body compartment-specific, protease–antiprotease balances and imbalances. For example, patients with severe SARS-CoV-2 exhibited an acute phase plasma AAT response similar to patients with severe nsARDS (Figure 1a). AAT in SARS-CoV-2 patient plasma was active against NE (Figure 2b) and exhibited the increased sialylation (Figure 5d and e), important for regulating neutrophil chemotaxis.9 The increased AAT levels in the plasma of subjects with severe SARS-CoV-2-ARDS or nsARDS was regulated largely by circulating IL-6, as shown by in vitro and in vivo inhibition with tocilizumab (Figures 5a,b,c and 6a). In vitro data suggested that approximately 24 h is required for IL-6 in plasma to increase AAT levels (Figure 5a), potentially rendering the lung with insufficient anti-protease protection during this time.

While patients with severe SARS-CoV-2 infection exhibited high levels of active AAT, in excess of NE, in their plasma, protease–anti-protease balance in the lung varied with compartment (airways versus alveolus; Figure 4b). In all the TA from SARS-CoV-2-infected subjects, a protease imbalance was observed with AAT mostly cleaved or complexed with NE, and detectable active free NE (Figure 3). On average, these TA were collected 11 ± 6-9 days from onset of symptoms and 1 day post ICU admission. In contrast, only one of the patients with nsARDS demonstrated active NE in their TA (airways) which differentiates this syndrome from SARS-CoV-2 ARDS (Figure 3b). This finding suggests that the AAT acute phase response in patients with SARS-CoV-2 ARDS is not sufficient to protect the proximal airways from NE-induced damage. A similar airway protease imbalance has been described in community acquired pneumonia43 and cystic fibrosis.44

AAT was not the only anti-protease affected by SARS-CoV-2. SLPI, the major locally produced anti-protease in the airways, was cleaved in TAs from SARS-CoV-2 unlike the uncleaved intact form of SLPI seen in nsARDS (Figure 3a). There was also reduced SLPI protein expression in airway epithelia of acutely infected SARS-CoV-2 lungs (Figure 4a). SLPI downregulation has been previously reported with suppression of Nrf2 signalling in SARS-CoV-2 infections35,36 and with other viral infections,72 and its absence diminishes the airway antiprotease protective shield.28 Thus, in subjects with severe SARS-CoV-2 infection, the proximal airway anti-protease and anti-inflammatory protection afforded by locally (airway) produced SLPI, in addition to systemically available AAT, is inadequate to protect against tissue damage. The potential deleterious consequences of this unopposed NE activity include direct tissue damage, impaired ciliary motility, increased mucin secretion, inactivated anti-inflammatory proteins, cleaved complement, complement receptors and immunoglobulins, and initiation of a cycle of inflammation in the lung.3 These sequelae are also seen in CF which has led to a series of studies into anti-protease therapy in this condition. Our data suggest this therapeutic option should be considered in SARS-CoV-2 infection. Already a number of small non-randomised controlled trials have suggested some benefit of AAT administration in SARS-CoV-2 infection using both aerosol and intravenous routes of administration.95 This raises a number of questions such as which route of administration would be preferable. Certainly in the context of its anti-protease effects and the site of protease-anti-protease imbalance in SARS-CoV-2 ARDS, aerosol delivery of AAT would seem most beneficial but it should also be noted that AAT possesses significant anti-inflammatory effects7 and in the context of the severe systemic inflammation seen in SARS-CoV-2 infection an intravenous
Another concern is when in the course of the condition such administration should take place and whether it should be given to all SARS-CoV-2 clinical phenotypes. That would require further study specifically to determine whether AAT therapy in SARS-CoV-2 infection mediates its effect mainly through its anti-protease, anti-inflammatory capabilities or through its ability to decrease SARS-CoV-2 entry into cells via its actions on TMPRSS2.

If AAT synthesis and secretion are beneficial responses to SARS-CoV-2 infection, might decreases in

**Figure 6.** AAT and IL-6 levels pre-and post (28 days) tocilizumab (8mg/kg) in ward level patients with SARS-CoV-2 infection with corresponding isoelectric focussing (IEF) gel.

a. Decrease in AAT plasma levels in ward level patients post tocilizumab (n = 10) (P < 0.0001) (paired T test). b. Maintenance of elevated IL-6 plasma levels in the same cohort of ward level patients throughout their 28 day course (ns=0.099, paired T test). c. Increased IL-6/AAT ratio at day 28 post tocilizumab (P = 0.046, paired T test). d. Glycosylation pattern pre- and post tocilizumab infusion as compared to ward level patients receiving standard of care (SOC), matched for a similar AAT level and inflammatory profile sampled at the same timepoints.
AAT synthesis secondary to molecular therapies be harmful? Monoclonal antibodies directed against the IL-6R, e.g., tocilizumab, have been tested in SARS-CoV-2. Reports of tocilizumab efficacy in SARS-CoV-2 have been mixed. A retrospective analysis revealed an association between tocilizumab administration and increased mortality, ICU admissions, mechanical ventilation and length of stay in subjects with SARS-CoV-2 infection. However, while the recently published results of the RECOVERY and REMAP-CAP trials showed no benefit from tocilizumab alone, they did suggest a benefit from the addition of tocilizumab to high-dose dexamethasone. Tocilizumab does not discriminate between classical or trans-IL-6 signalling and, therefore, blocks many anti-inflammatory effects of IL-6, including AAT induction. As observed in the present study, the acute phase AAT response may be required to dampen airway inflammation and prevent airway damage during SARS-CoV-2 infections. The noticeable decrease in plasma AAT levels in patients treated with tocilizumab and the coinciding increase in their IL-6/AAT ratio at day 28 of treatment demonstrates disruption to the normal IL-6-AAT signalling pathway (Figure 6). Not only does this downregulate AAT production in vivo but also ST6GAL1, as seen by the resolution of hyperglycosilated M0, M1 AAT bands in patient plasma (Figure 6d). This finding also denotes a reduction in the ability of AAT to bind IL-8, essential for regulating chemotaxis during inflammatory processes, as shown in this study. These data suggest that in future IL-6 blockade trials, special care has to be taken to ensure that inhibition of AAT induction does not worsen an already precarious protease-anti-protease balance in the lungs. In this regard, a more targeted approach, perhaps aimed at IL-6 trans-signalling, using compounds such as soluble gp130, could be considered that would leave the classical IL-6-hepatic AAT synthesis/secretion pathway unaffected or, alternatively, therapies aimed at inhibiting IL-6 should be accompanied by concomitant administration of exogenous AAT.

A limitation of this study is that our patient samples were collected from several different centers. With regards airway samples, the majority of TA samples were from UNC (n = 10), where they were treated with 6M urea for safe handling. As a result, FRET analysis of protease activity analysis was not possible in these samples. Five additional TA’s were collected from Beaumont hospital which were suitable for NE activity.
In summary, this study demonstrates that AAT responses to SARS-CoV-2 infection are compartmentalized with an appropriate increase in plasma and alveoli but deficient responses in airways (Figure 7). These data suggest administration of intravenous or aerosolized AAT to SARS-CoV-2-infected subject airways may be an appropriate therapeutic option. Finally, according to these data, caution should be exercised in SARS-CoV-2-infected individuals with respect to administration of IL-6 blocking therapies.

Declaration of interests
Oisin F McElvaney, Takeanori Asakura, Oliver J McElvaney, Suzanne I Meinig, Jose I Torres-Castillo, Robert S Hogan, Claudie Gabillard, Mark P Murphy, Leigh B. Thorne, Alain Borczuk, Emer P Reeves, Ross. E. Zumwalt, Yu Mikami, Tomás Carroll, Kenichi Okuda, Grace Hogan, Jennifer Clarke, Natalie L McEvoy, Ger Curley, Matthew C Wolfgang Cormac McCarthy, Patrick W Mallon and Richard C. Boucher have declared no conflict of interest.

Noel G McElvaney reports grants from Phfarma, Chiesi, consulting fees from Vertex, Takeda, Intella, non-financial support and fees as a judge for an award with Danmarks Tekniske Universitet.

Contributors
Oisin F McElvaney and Noel G McElvaney conceptualized the study; Oisin F McElvaney, Richard C. Boucher, Oliver J McElvaney and Noel G McElvaney designed the study; Patrick W Mallon, Cormac McCarthy, Grace Hogan, Jennifer Clarke, Natalie L McEvoy, Yu Mikami, Kenichi Okuda, Suzanne I Meinig, Jose I Torres-Castillo, Ross. E. Zumwalt, Leigh B. Thorne and Alain Borczuk recruited patients and collected and processed samples; Oisin F McElvaney, Takeanori Asakura, Mark P Murphy and Claudie Gabillard performed experiments; Oisin F McElvaney, Takeanori Asakura, Claudie Gabillard and Mark Murphy performed statistical analyses; Oisin F McElvaney, Matthew C Wolfgang, Richard C. Boucher, Mark P Murphy, Tomas Carroll, Emer P Reeves, Robert S Hagan and Noel G McElvaney co-wrote the manuscript. Oisin F McElvaney, Mark P Murphy, Tomas Carroll and Noel G McElvaney verified the underlying data. All authors read and approved the final version of the manuscript.

Acknowledgments
This work was supported in part through the Health Research Board (HRB) Ireland Impact award 2021 and Alpha 1 Foundation (US). We would like to acknowledge the following grants: NIH Serological Sciences Network, grant U54CA260543-01 (RSH, MCW); NIH National Heart, Lung, and Blood Institute (NHBLI) grants UH3 HL123645, R01 HL136961, and P01 HL108808 (RBC); and NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant P30 DK65988 (RBC).

Data sharing statement
The data collected for the study, including individual participant data and a data dictionary defining each field in the set, that would identify individual patients will not be made available due to GDPR however de-identified participant data, is available. The study protocols, and informed consent forms will be made available with publication if desired with a signed data access agreement. Enquiries regarding access to research data should be sent to the corresponding author via email.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2022.103894.

References
1 Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):914–941.
2 Johns Hopkins coronavirus resource center 11.10.21 2022.
3 Strnad P, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382(15):1443–1455.
4 Azouz NP, Klinger AM, Callahan V, et al. Alpha 1 antitrypsin is an inhibitor of the SARS-CoV-2-priming protease TMPRSS2. Pathog Immun. 2021;6(1):75–74.
5 Geraghty P, Ragan MP, Greene CM, et al. Neutrophil elastase upregulates cathepsin B and matrix metalloprotease-2 expression. J Immunol. 2007;179(9):5871–5878.
6 McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med. 2020;202(6):812–821.
Articles

7 McElvaney OJ, Hobbs BD, Qiao D, et al. A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. JBioMed. 2020;61:30162.

8 Rose-John S. Interleukin-6 signalling in health and disease. F1000Research. 2020;9:1013. F1000 Faculty Rev.

9 McCarthy C, Dunlea DM, Salduva R, et al. Glycosylation repurposes alpha-1 antitrypsin for resolution of community-acquired pneumonia. Am J Respir Crit Care Med. 2018;197(10):1346–1349. https://doi.org/10.1164/rccm.201709-1934LE.

10 McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor relates of fatal outcomes in critically ill COVID-19 patients. J Immunol. 2020;202(8):2240–2253. https://doi.org/10.1183/09031936.02.00253202. PMID: 12108856.

11 Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1B and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062–1073.

12 Korkmaz B, Attucci S, Juliano MA, et al. Measuring elastase, proteinase 3 and cathepsin G activities at the surface of human neutrophils with fluorescence resonance energy transfer substrates. Nat Protoc. 2008;3(6):991–1002. https://doi.org/10.1038/nprot.2008.63.

13 Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 2020;182(2):23429-446.e14. https://doi.org/10.1016/j.cell.2020.05.042. Epub 2020 May 27. PMID: 32426266; PMCID: PMC7250779.

14 Zerimech F, Hennache G, Bellon F, et al. Evaluation of a new Sebia isoelectrofocusing kit for alpha 1-antitrypsin phenotyping with the Hydrazys System. Clin Chem Lab Med. 2008;46(2):260–263. https://doi.org/10.1515/CCLM.2008.016. PMID: 18075632.

15 Reeves EP, Dunlea DM, McQuillan K, et al. Circulating truncated alpha-1 antitrypsin glycoprotein in patient plasma retains anti-inflammatory capacity. J Immunol. 2009;182(8):4240–4253. PMID: 19766179.

16 Youngs J, Provine NM, Lim N, et al. Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathog. 2021;17(7):e1009384.

17 Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–469.

18 Bennett KE, Mullooly M, O’Loughlin M, et al. Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: a national surveillance study. Lancet Reg. Health Eur. 2021;3:100097.

19 Eskandari A, Brojakowska A, Bisserier M, et al. Retrospective analysis of demographic factors in COVID-19 patients entering the Mount Sinai health system. PLoS One. 2021;16(7):e254707.

20 Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.

21 Bingle L, Cross SS, High AS, et al. WDFC2 (HFE): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;7:161. https://doi.org/10.1186/1465-9921-7-61. PMID: 16609012.

22 Cotter A, Wallace D, McCarthy C, et al. The COVIRLo2a Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):798. https://doi.org/10.1186/s13063-020-04680-w. PMID: 32883528; PMCID: PMC7468092.

23 Greene C, Taggart C, Lowe G, Gallagher P, McElvaney N, O’Neill S. Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia. J Infect Dis. 2003;188(5):769–776.

24 Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets. 2008;12(2):145–157.

25 Iizuka T, Ishii Y, Itoh K, et al. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells. 2005;10(12):1113–1125.

26 Olagnier D, Farahani E, Thyrsted J, et al. SARS-CoV2-mediated suppression of NRF2-signalling reveals potent antiviral and anti-inflammatory activity of 4-oxyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11(4938).

27 Fakogiou E, Wilson SS, Mesquita PM, et al. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol. 2008;82(19):9337–9344. https://doi.org/10.1128/JVI.02.00253208. Epub 2008 Jul 30. PMID: 18607158; PMCID: PMC2145054.

28 Betsuyaku T, Takeyabu K, Tanino M, Nishimura M. Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema. Eur Respir J. 2002;19(6):1051–1057. https://doi.org/10.1183/09031936.02.00253208. PMID: 12108566.

29 Ritzmann F, Chitirala P, Krüger N, et al. Therapeutic application of alpha-1 antitrypsin in COVID-19. Am J Respir Crit Care Med. 2021;204(2):224–227. https://doi.org/10.1164/rccm.202104-0511LE. PMID: 31961754.

30 Li M, Yoo EJ, Baram M, et al. Tocilizumab in the management of COVID-19: a preliminary report. Am J Med Sci. 2020. https://doi.org/10.1016/j.amjem.2020.11.005. S0002-9629(20)30491-2PMID: 31520502.

31 Gordon AC, Mounsey PR, Ali-Beidi F, et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N Engl J Med. 2021 NEJMoa2109473.

32 McElvaney NG, Hubbard RC, Berrir P, et al. Aerosol alpha-1 antitrypsin treatment for cystic fibrosis. Lancet. 1991;337(8738):392–394.

33 Griese M, Scheuch G. Delivery of alpha-1 antitrypsin to airways. Ann Am Thorac Sci. 2016;3(Suppl 4):S346–S351.